{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000062","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.910906+00:00","generated_at":"2026-06-09T02:45:16.273481+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"vTv Therapeutics sells Reneo shares for $4.4M to fund cadisegliatin Phase 3","bullets":["Sold all Reneo common shares held under 2017 license for ~$4.4M gross proceeds.","Proceeds support preparations for launch of cadisegliatin Phase 3 in type 1 diabetes.","Remains eligible for up to $94.5M in clinical, regulatory & commercial milestones.","Eligible for tiered royalties (mid-single to low teens) on potential net sales of mavodelpar."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000062","json":"https://secwatch.observer/filing/0001641489-23-000062.json","markdown":"https://secwatch.observer/filing/0001641489-23-000062.md","text":"https://secwatch.observer/filing/0001641489-23-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/0001641489-23-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/vtvt-20231030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:45:16.273481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18d17c3d5d842b29c27f38d697d431ba947a4702","claim":"vTv Therapeutics Inc. entered into Common Stock Repurchase Agreement with Reneo Pharmaceuticals, Inc. valued at approximately $4.4 million (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary of vTv Therapeutics, Inc. (the “Company”) entered into a Common Stock Repurchase Agreement (the \"Repurchase Agreement\") with Reneo Pharmaceuticals, Inc. (“Reneo”) pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million for the Reneo common stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/0001641489-23-000062-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Reneo Pharmaceuticals, Inc."},{"label":"Value","value":"approximately $4.4 million"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}